TDB-DST Backs Indo-Singapore CAR-T Cell Therapy Project for Multiple Myeloma
The initiative focuses on creating a next-generation Chimeric Antigen Receptor T-cell therapy that simultaneously targets BCMA and CD19 markers found on Multiple Myeloma cells. The therapy aims to improve treatment effectiveness and extend remission duration in patients suffering from relapsed or treatment-resistant blood cancer.
Under the project, Helix Cell Therapeutics will undertake the development, manufacturing, and Phase-I clinical evaluation of the dual-targeting CAR-T cells. The therapy is intended for patients who have exhausted conventional treatment options and currently face limited therapeutic alternatives.
CAR-T therapy works by genetically engineering a patient’s T-cells to identify and destroy cancer cells. The dual-targeting approach represents a significant advancement over existing single-marker CAR-T therapies and is expected to improve long-term clinical outcomes in difficult-to-treat Multiple Myeloma cases.
TDB Secretary Rajesh Kumar Pathak said that advanced cell and gene therapies are shaping the future of precision healthcare and have transformative potential in treating previously incurable diseases. He noted that the Indo-Singapore collaboration would strengthen India’s position in next-generation biotechnology and affordable healthcare innovation.
The project aligns with the Government of India’s vision of boosting indigenous capabilities in advanced biologics, precision medicine, and healthcare technologies under the broader framework of Aatmanirbhar Bharat while deepening India-Singapore cooperation in biomedical innovation.
